Retatrutide TRIUMPH-1: 28.3% Weight Loss in Phase 3 Obesity Trial
On May 21, 2026, Eli Lilly reported topline results from TRIUMPH-1, the first Phase 3 obesity trial for retatrutide. The 12 mg dose produced 28.3% average weight loss at 80 weeks and 30.3% at 104 weeks in a higher-BMI subgroup. These are the strongest weight-loss numbers reported for a non-surgical intervention to date.
Headline efficacy results
The main trial endpoint at 80 weeks showed the 12 mg retatrutide dose produced a mean weight loss of 70.3 lb, equal to 28.3% of starting body weight. The 9 mg dose and 4 mg dose also met primary and key secondary endpoints, with weight loss scaling roughly linearly with dose. Placebo participants lost a small amount of weight, well within the range of behavioral intervention effects.
The 104-week extension data come from a subgroup of participants with baseline BMI of at least 35. In this group, 12 mg retatrutide produced an average loss of 85.0 lb, equal to 30.3% of starting body weight. The extension dataset is what generated the most attention, since it crosses into a range previously achievable only with bariatric surgery.
| Cohort | Duration | Weight loss (lb) | Percent of body weight |
|---|---|---|---|
| Retatrutide 12 mg (main trial) | 80 weeks | 70.3 | 28.3% |
| Retatrutide 12 mg (BMI ≥35 extension) | 104 weeks | 85.0 | 30.3% |
TRIUMPH-1 trial design
TRIUMPH-1 was a randomized, double-blind, placebo-controlled Phase 3 trial enrolling 2,339 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were randomized to weekly subcutaneous injections of placebo or one of three retatrutide doses: 4 mg, 9 mg, or 12 mg. The treatment period ran 80 weeks for the main endpoint with a 24-week extension for the BMI ≥35 subgroup.
Dose escalation followed Lilly\'s established incretin titration approach. Participants started low and stepped up every 4 weeks to reduce gastrointestinal side effects during the early weeks of treatment. The trial used standard lifestyle counseling as the background intervention so that the placebo arm represented the realistic counterfactual of behavior change alone.
Dose response: how much do 4 mg and 9 mg lose?
All three doses met the primary endpoint, meaning each produced statistically and clinically meaningful weight loss versus placebo. Lilly has not yet released exact percentages for 4 mg and 9 mg, but the Phase 2 dose-finding study suggests weight loss scales roughly linearly with dose at this range. Phase 2 reported approximately 17% at 8 mg and 24% at 12 mg, so 9 mg is likely to land in the 20-22% range at 80 weeks and 4 mg in the 12-15% range.
This matters for real-world prescribing. Patients who cannot tolerate the 12 mg dose due to GI side effects can still expect tirzepatide-comparable results from the 9 mg dose, and semaglutide-comparable results from 4 mg. The dose-response curve means there is no single "right" dose. Pick the dose that balances target weight loss against tolerability.
How retatrutide compares to tirzepatide and semaglutide
Tirzepatide produced 20.9% weight loss at the 15 mg dose at 72 weeks in SURMOUNT-1. Semaglutide produced 14.9% at 2.4 mg at 68 weeks in STEP 1. Retatrutide 12 mg at 28.3% over 80 weeks represents a 35% relative improvement over tirzepatide and an 89% improvement over semaglutide.
The 104-week extension number of 30.3% in the BMI ≥35 subgroup crosses an important threshold. Bariatric surgery typically produces 25-35% total body weight loss at 2 years. If retatrutide can reproduce these numbers across broader populations, it becomes the first medication that reaches surgical-grade outcomes without surgery.
| Drug | Trial | Top dose | Duration | Avg weight loss |
|---|---|---|---|---|
| Semaglutide | STEP 1 | 2.4 mg | 68 weeks | 14.9% |
| Tirzepatide | SURMOUNT-1 | 15 mg | 72 weeks | 20.9% |
| Retatrutide | TRIUMPH-1 | 12 mg | 80 weeks | 28.3% |
| Retatrutide (BMI ≥35 ext.) | TRIUMPH-1 | 12 mg | 104 weeks | 30.3% |
Why a triple agonist outperforms dual agonists
Semaglutide is a single agonist of the GLP-1 receptor. Tirzepatide adds GIP receptor agonism. Retatrutide adds a third: glucagon receptor agonism. Each receptor contributes different effects to the overall metabolic response. See our retatrutide encyclopedia entry for the underlying pharmacology.
The glucagon receptor is the difference-maker. Glucagon agonism increases resting energy expenditure, meaning the body burns more calories at rest. GLP-1 and GIP work primarily by reducing intake and improving insulin handling, which restricts calories in. Glucagon adds the calories-out side of the equation. The combination is why retatrutide produces a step-change in weight loss rather than incremental improvement over tirzepatide.
Safety profile
Lilly\'s announcement described safety as consistent with the incretin class. The predominant adverse events were gastrointestinal: nausea, vomiting, diarrhea, and constipation. Most events were mild to moderate and occurred during dose escalation, then resolved or improved with continued treatment.
The Phase 2 trial flagged a transient heart rate increase of 6-9 beats per minute that warrants monitoring. The Phase 2 study also reported dose-dependent GI tolerability, with the 12 mg dose having higher discontinuation rates than 8 mg. Detailed discontinuation rates and serious adverse event data from TRIUMPH-1 will publish with the full congress presentation.
Black box warnings carried over from the GLP-1 class apply to retatrutide as well: medullary thyroid carcinoma (animal data), pancreatitis risk, and gallbladder disease associated with rapid weight loss. See our guide on retatrutide side effects for the full risk profile from Phase 2 plus expected Phase 3 considerations.
Cardiometabolic effects
Lilly\'s announcement reported "improvements in cardiometabolic risk factors" alongside weight loss but did not provide specific numbers. Phase 2 data showed improvements in HbA1c, lipid profile, blood pressure, and waist circumference that tracked with weight loss magnitude. Lilly is running a separate cardiovascular outcomes trial (TRIUMPH-Outcomes) to determine whether retatrutide reduces hard cardiovascular events the way semaglutide did in SELECT.
The cardiometabolic side of the data matters for the FDA filing. Approval for chronic weight management requires demonstrating that the weight loss translates into improved health outcomes, not just a smaller number on the scale. A 28-30% weight loss should automatically improve blood pressure, lipids, and glycemic control, but the FDA wants this documented.
What this means for the FDA timeline
TRIUMPH-1 is one piece of the Phase 3 program. Other trials in the TRIUMPH series cover type 2 diabetes (TRIUMPH-2, TRIUMPH-4), maintenance after intensive lifestyle intervention, and the cardiovascular outcomes trial. Lilly typically files for FDA approval after the obesity dataset is mature and at least one diabetes trial has reported.
Industry analysts expect Lilly to file an NDA in late 2026 or early 2027. FDA review under priority designation typically takes 6-10 months. A realistic approval window is mid-2027 to late 2028. See our retatrutide FDA approval timeline for the full regulatory pathway.
Access before approval
Retatrutide is not legally available in the US as a prescription drug. Three illegal or gray-market routes exist, none of which we recommend:
- Research peptide suppliers sell retatrutide as a research chemical with "not for human consumption" labeling. Quality, purity, and identity are unverified. See our framework for evaluating peptide vendors.
- Compounding pharmacies previously sold compounded retatrutide. The April 2026 FDA 503B bulks list proposal effectively closes this route for the major GLP-1s. See our guide on the compounded GLP-1 shortage and FDA action.
- International pharmacies from jurisdictions with looser controls. Import is illegal under the Federal Food, Drug, and Cosmetic Act and product authenticity cannot be verified.
The legal route is to wait for FDA approval. In the meantime, tirzepatide remains the highest-efficacy approved option for weight loss at around 21% mean reduction. See our Zepbound vs Wegovy comparison and our tirzepatide telehealth guide for current access.
Bottom line
TRIUMPH-1 confirms what Phase 2 suggested: triple agonism produces substantially more weight loss than dual or single agonism, at the cost of GI tolerability that scales with dose. The 28.3% at 80 weeks and 30.3% at 104 weeks are the strongest numbers ever reported for a non-surgical obesity intervention. Approval is not imminent, but the data make retatrutide the heir apparent to tirzepatide as the leading prescription weight loss drug.
For most patients today, the practical takeaway is: stay on tirzepatide or semaglutide if you are on one and it is working. Do not chase research-grade retatrutide. Wait for FDA approval, then talk to your prescriber about whether the 8-10 percentage points of additional weight loss are worth switching for.
Sources
- Eli Lilly press release (May 21, 2026): TRIUMPH-1 topline results
- AJMC: Retatrutide Achieves Up to 30.3% Average Weight Loss
- Pharmacy Times: Bariatric-level weight loss in TRIUMPH-1
- HCPLive: Retatrutide meets weight loss endpoints in Phase 3 obesity trial
- Patient Care Online: Phase 3 data show up to 28% weight loss
Frequently Asked Questions About Retatrutide
On the 12 mg dose, participants lost an average of 70.3 lb (28.3% of starting body weight) at 80 weeks. In a 104-week extension subgroup with baseline BMI ≥35, the 12 mg group reached 85.0 lb average loss (30.3% of starting body weight). All three studied doses (4 mg, 9 mg, 12 mg) met the primary and key secondary endpoints.
Eli Lilly announced TRIUMPH-1 topline Phase 3 results on May 21, 2026. Full results are expected at a major medical congress later in 2026 with peer-reviewed publication to follow.
The master trial enrolled 2,339 adults with obesity or overweight with weight-related comorbidities. Participants were randomized in a double-blind, placebo-controlled design across the 4 mg, 9 mg, 12 mg, and placebo arms. A smaller subgroup with baseline BMI ≥35 continued for an additional 24 weeks, generating the 104-week dataset.
Tirzepatide at the 15 mg dose produced 20.9% weight loss at 72 weeks in SURMOUNT-1. Semaglutide at 2.4 mg produced 14.9% at 68 weeks in STEP 1. Retatrutide 12 mg at 28.3% over 80 weeks is the highest weight loss reported in a Phase 3 obesity trial of a non-surgical intervention to date.
Retatrutide activates three receptors: GLP-1 (appetite suppression and insulin response), GIP (insulin sensitivity), and glucagon (energy expenditure). Adding glucagon agonism increases resting energy expenditure in a way that pure GLP-1 or dual GLP-1/GIP molecules cannot. The result is more weight loss for the same level of caloric restriction.
Lilly's announcement described the safety profile as consistent with the incretin class — predominantly gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation), mostly mild to moderate, occurring during dose escalation. Detailed adverse event rates and discontinuation numbers will publish with the full results. The Phase 2 trial showed dose-dependent GI tolerability and a transient heart rate increase that warrants monitoring.
Lilly has not announced an NDA filing date, but TRIUMPH-1 is one of multiple Phase 3 trials in the program. Industry analysts expect an NDA filing in late 2026 or early 2027 with potential FDA approval in 2027 or 2028. Approval depends on Lilly assembling the full TRIUMPH dataset across obesity and type 2 diabetes indications.
Retatrutide is not FDA-approved and not commercially available as a prescription drug. It is sold by research peptide suppliers as a research chemical, but those products are unregulated, unverified, and not legal for human use. See our guides on the research peptide market and on how the FDA 503B exclusion affects compounded GLP-1 access.
Probably not immediately, even after approval. New drugs launch with limited supply and high cost. Tirzepatide and semaglutide have years of real-world data, established insurance coverage, and broad clinician familiarity. Retatrutide will likely be reserved for patients who fail to reach goal weight on existing GLP-1s or who need the additional 8-10 percentage points of weight loss.